Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

Abstract

This study attempted to assess the incidence and outcome of anthracycline cardiotoxicity and the role of dexrazoxane as a cardioprotectant in childhood solid tumors. The dexrazoxane group included 47 patients and the control group of historical cohort included 42. Dexrazoxane was given in the 10:1 ratio to doxorubicin. Fractional shortening and systolic and diastolic left ventricular diameters were used to assess the cardiac function. The median follow-ups were 54 months in the dexrazoxane group and 86 months in the control group. The mean cumulative doses of doxorubicin were 280.8+/-83.4 mg/m(2) in the dexrazoxane group and 266.1+/-75.0 mg/m(2) in the control group. The dexrazoxane group experienced significantly fewer cardiac events (27.7% vs. 52.4%) and less severe congestive heart failure (6.4% vs. 14.3%) than the control group. Thirteen cardiotoxicities including one cardiac death and 2 congestive heart failures occurred in the dexrazoxane group, and 22 cardiotoxicities including 2 cardiac deaths and 4 congestive heart failures, in the control group. Five year cardiac event free survival rates were 69.2% in the dexrazoxane group and 45.8% in the control group (P=0.04). Dexrazoxane reduces the incidence and severity of early and late anthracycline cardiotoxicity in childhood solid tumors.

• Authors: Hyoung Soo Choi, Eun Sil Park, Hyoung Jin Kang, Hee Young Shin, Chung Il Noh, Yong Soo Yun, Hyo Seop Ahn, Jung Yun Choi
• Journal: Journal of Korean medical science (J Korean Med Sci) Vol. 25 Issue 9 Pg. 1336-42 (Sep 2010) ISSN: 1598-6357 [Electronic] Korea (South)
• PMID: 20808678 (Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibiotics, Antineoplastic
• Cardiovascular Agents
• Razoxane
• Doxorubicin

Topics

• Adolescent
• Antibiotics, Antineoplastic (adverse effects)
• Cardiomyopathies (chemically induced, prevention & control)
• Cardiovascular Agents (therapeutic use)
• Child
• Child, Preschool
• Cohort Studies
• Disease-Free Survival
• Doxorubicin (adverse effects)
• Echocardiography
• Female
• Follow-Up Studies
• Heart Failure (chemically induced, prevention & control)
• Humans
• Infant
• Male
• Neoplasms (drug therapy, mortality)
• Razoxane (therapeutic use)
• Ventricular Function, Left (physiology)